

Luis Costa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4685331/publications.pdf>

Version: 2024-02-01

106
papers

4,255
citations

159358

30
h-index

114278

63
g-index

109
all docs

109
docs citations

109
times ranked

5417
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-181a restricts human β^1 T cell differentiation by targeting Map3k2 and Notch2. <i>EMBO Reports</i> , 2022, 23, e52234.	2.0	5
2	Laparoscopic Vena Cava Thrombectomy and Radical Nephrectomy in a Malignant Pheochromocytoma Case. <i>Acta Urológica Portuguesa</i> , 2022, 37, 27-31.	0.1	0
3	Predictive and Therapeutic Implications of a Novel PLC β 1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1203-1216.	3.2	7
4	Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning. <i>Oncotarget</i> , 2022, 13, 237-256.	0.8	2
5	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases. <i>Cancers</i> , 2022, 14, 893.	1.7	2
6	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	5.1	4
7	Bone Health in Metastatic Cancer. <i>Seminars in Oncology Nursing</i> , 2022, 38, 151278.	0.7	4
8	Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress. <i>Nutrients</i> , 2022, 14, 2102.	1.7	4
9	Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9067-9067.	0.8	1
10	Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 107-107.	0.8	6
11	HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. <i>Npj Genomic Medicine</i> , 2021, 6, 13.	1.7	17
12	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. <i>European Journal of Cancer</i> , 2021, 144, 351-359.	1.3	2
13	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. <i>Targeted Oncology</i> , 2021, 16, 357-367.	1.7	13
14	Circulating tumor cell detection methods in renal cell carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103331.	2.0	15
15	The Roadmap of RANKL/RANK Pathway in Cancer. <i>Cells</i> , 2021, 10, 1978.	1.8	29
16	Prostate Ewing Sarcoma/PNET: A case of long survival in a highly aggressive malignancy. <i>Urology</i> , 2021, 154, e11-e12.	0.5	4
17	Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique. <i>Journal of Mathematical Biology</i> , 2021, 83, 39.	0.8	1
18	HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device. <i>Cancers</i> , 2021, 13, 4446.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in Metastatic Mucosal Melanoma with Disseminated Intravascular Coagulation: A Case of Success. <i>Case Reports in Immunology</i> , 2021, 2021, 1-5.	0.2	3
20	c-Met expression in renal cell carcinoma with bone metastases. <i>Journal of Bone Oncology</i> , 2020, 25, 100315.	1.0	10
21	Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 768-774.	0.3	7
22	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83.	18.1	246
23	Impact of Extraskelatal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases. <i>Cancers</i> , 2020, 12, 2034.	1.7	5
24	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. <i>Targeted Oncology</i> , 2020, 15, 301-315.	1.7	37
25	Rapid desensitization to antineoplastic drugs in an outpatient immunoallergy clinic. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 325-333.e1.	0.5	28
26	Prognostic factors for patients treated with abiraterone. <i>Future Science OA</i> , 2020, 6, FSO436.	0.9	4
27	Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 603-623.	2.7	50
28	Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2-breast cancer. <i>Oncotarget</i> , 2020, 11, 1714-1728.	0.8	15
29	360 Health Analysis (H360) – A Proposal for an Integrated Vision of Breast Cancer in Portugal. <i>The Journal of Breast Health</i> , 2020, 16, 91-98.	0.4	2
30	Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues. <i>Radiotherapy and Oncology</i> , 2019, 141, 256-261.	0.3	11
31	Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study. <i>Clinical Breast Cancer</i> , 2019, 19, e654-e667.	1.1	4
32	Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1114-1124.	1.1	21
33	Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 13.	1.5	3
34	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. <i>Cancer Treatment Reviews</i> , 2019, 76, 57-67.	3.4	85
35	Cancer Treatment-Induced Bone Loss (CTIBL)., 2019, , 296-303.		1
36	Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 695.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 19761.	1.6	41
38	Bone Metastasis. , 2019, , 1115-1137.		0
39	Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. <i>Breast</i> , 2018, 37, 107-113.	0.9	6
40	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 113-131.	0.8	19
41	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 117-133.	0.8	58
42	Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. <i>European Journal of Cancer</i> , 2017, 71, 80-94.	1.3	74
43	Adjuvant zoledronic acid to treat breast cancer: not for all. <i>Lancet Oncology</i> , The, 2017, 18, 1437-1439.	5.1	4
44	Radionuclides in oncology clinical practice – review of the literature. <i>Dalton Transactions</i> , 2017, 46, 14475-14487.	1.6	4
45	Bone metastasis risk factors in breast cancer. <i>Ecancermedalscience</i> , 2017, 11, 715.	0.6	79
46	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 212-212.	0.8	3
47	Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5028-5028.	0.8	1
48	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16537-e16537.	0.8	0
49	Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1415.	1.8	35
50	N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskelatal Metastases. <i>Oncologist</i> , 2016, 21, 1418-1426.	1.9	17
51	Organizaç�o e implementaç�o de uma consulta de cardio�oncologia. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 485-494.	0.2	9
52	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study. <i>Breast</i> , 2016, 29, 68-73.	0.9	8
53	Dynamic modeling of bone metastasis, microenvironment and therapy. <i>Journal of Theoretical Biology</i> , 2016, 391, 1-12.	0.8	19
54	Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 170-178.e3.	1.0	70

#	ARTICLE	IF	CITATIONS
55	Health resource utilization associated with skeletal-related events: results from a retrospective European study. <i>European Journal of Health Economics</i> , 2016, 17, 711-721.	1.4	16
56	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. <i>Journal of Clinical Oncology</i> , 2016, 34, 5024-5024.	0.8	0
57	Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation. <i>Anticancer Research</i> , 2016, 36, 2227-32.	0.5	2
58	Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	6
59	Targeting bone metastases in prostate cancer: improving clinical outcome. <i>Nature Reviews Urology</i> , 2015, 12, 340-356.	1.9	87
60	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. <i>Breast Cancer Research</i> , 2015, 17, 140.	2.2	143
61	Bone remodeling markers and bone metastases: From cancer research to clinical implications. <i>BoneKey Reports</i> , 2015, 4, 668.	2.7	45
62	Bone Metastases. , 2015, , 867-889.		0
63	Which bisphosphonate to treat bone metastases?. <i>Lancet Oncology</i> , The, 2014, 15, 15-16.	5.1	8
64	Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. <i>Supportive Care in Cancer</i> , 2014, 22, 679-687.	1.0	146
65	New Targeted Therapies for Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 235-246.	0.1	0
66	Biological assessment of novel bisphosphonate-containing ^{99m} Tc/Re-organometallic complexes. <i>Journal of Organometallic Chemistry</i> , 2014, 760, 197-204.	0.8	14
67	The global cancer genomics consortium's third annual symposium: from oncogenomics to cancer care. <i>Genes and Cancer</i> , 2014, 5, 64-70.	0.6	1
68	Treatment of bone metastases before the onset of pain. <i>International Journal of Clinical Oncology</i> , 2013, 18, 531-538.	1.0	17
69	Carboplatin-, Oxaliplatin-, and Cisplatin-specific IgE: Cross-reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 494-500.	2.0	75
70	Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing. <i>Scientific Reports</i> , 2013, 3, 2256.	1.6	63
71	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features – An exploratory analysis of placebo-controlled trials. <i>Journal of Bone Oncology</i> , 2013, 2, 70-76.	1.0	34
72	The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis. <i>Tumor Biology</i> , 2013, 34, 1979-1989.	0.8	23

#	ARTICLE	IF	CITATIONS
73	MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 3761-3770.	0.4	61
74	RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. <i>PLoS ONE</i> , 2013, 8, e63153.	1.1	66
75	The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. <i>ISRN Hepatology</i> , 2013, 2013, 1-9.	0.9	4
76	Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5079-5079.	0.8	2
77	Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism. <i>PLoS ONE</i> , 2013, 8, e76307.	1.1	9
78	N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9634-9634.	0.8	0
79	Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines. <i>Anticancer Research</i> , 2013, 33, 1983-7.	0.5	5
80	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. <i>Oncotargets and Therapy</i> , 2012, 5, 409.	1.0	14
81	Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment. <i>Prostate Cancer</i> , 2012, 2012, 1-11.	0.4	79
82	Antiresorptive treatment options and bone health in cancer patientsâ€”safety profiles and clinical considerations. <i>Cancer Treatment Reviews</i> , 2012, 38, 815-824.	3.4	15
83	Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 453-457.	1.1	10
84	Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 155-164.	1.7	41
85	Elevated pretreatment serum activinÂA and progression-free and overall survival in trastuzumab-treated metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 607-607.	0.8	0
86	Elevated pretreatment serum activinÂA and progression-free and overall survival in trastuzumab-treated metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 38-38.	0.8	0
87	Lactoferrinâ€”Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple-Negative Breast Cancer Phenotypes. <i>Cancer Research</i> , 2011, 71, 7259-7269.	0.4	36
88	Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1125-1132.	0.8	1,090
89	Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?. <i>Breast Disease</i> , 2011, 33, 59-69.	0.4	14
90	Consensus on the utility of bone markers in the malignant bone disease setting. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 411-432.	2.0	84

#	ARTICLE	IF	CITATIONS
91	Anticancer evidence for zoledronic acid across the cancer continuum. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, S31-S37.	2.0	25
92	Reply to S.M. Sorscher et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 2736-2737.	0.8	2
93	Phase I Trial of Zoledronic Acid + Imatinib Mesylate (Gleevec) in Patients With Bone Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 75-78.	0.6	9
94	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 767-779.	1.1	62
95	Zoledronic Acid: Its Use in the Treatment of Breast Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2353.	0.4	0
96	Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases. <i>Oncologist</i> , 2010, 15, 1147-1158.	1.9	42
97	Effect of bisphosphonates on pain and quality of life in patients with bone metastases. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 163-174.	12.5	136
98	^{99m} Tc-Tricarbonyl Complexes Functionalized with Anthracenyl Fragments: Synthesis, Characterization, and Evaluation of Their Radiotoxic Effects in Murine Melanoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 551-563.	0.7	24
99	Bone Metastases From Advanced Cancers. <i>Clinical Journal of Oncology Nursing</i> , 2009, 13, 701-710.	0.3	13
100	Impact of skeletal complications on patients'™ quality of life, mobility, and functional independence. <i>Supportive Care in Cancer</i> , 2008, 16, 879-889.	1.0	175
101	Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases. <i>Supportive Cancer Therapy</i> , 2006, 3, 143-153.	0.3	25
102	Biochemical Markers and Skeletal Metastases. <i>Clinical Orthopaedics and Related Research</i> , 2003, 415, S138-S147.	0.7	32
103	Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status. <i>Journal of Clinical Oncology</i> , 2002, 20, 850-856.	0.8	176
104	Biochemical markers and skeletal metastases. <i>Cancer</i> , 2000, 88, 2919-2926.	2.0	169
105	The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. <i>Oncotarget</i> , 0, 7, 41380-41389.	0.8	7
106	Exploring new pathways in endocrine-resistant breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 337-361.	0.5	2